Many of those genes inhibited by SID peptide treatment (CD44, TGFβR2, LEF1, TCF7L2, FGF2, FGF5, ID2, PIK3R3) (Figure 3A, Table 2-3) are known as direct TGIF1 targets in myeloid leukemia [47] or embryonic stem cells [48]. This evidence concerns the gene ID2 and myeloid leukemia.